Sathisaran, IndumathiIndumathiSathisaranDevidas Bhatia, DhirajDhirajDevidas BhatiaVishvanath Dalvi, SameerSameerVishvanath Dalvi2025-08-312025-08-312020-09-2510.1016/j.ijpharm.2020.1196672-s2.0-85088633437https://d8.irins.org/handle/IITG2025/2400132702448Curcumin (CUR) is a Biopharmaceutics Classification System (BCS) class IV drug with poor aqueous solubility and low permeability. The dissolution of CUR can be enhanced through the cocrystallization approach. In this work, we report a new cocrystal phase of CUR with trimesic acid (TMA) with the enhanced dissolution of CUR. Cytotoxicity and cell invasion assays were conducted on (2D) monolayers and three-dimensional (3D) tumor models of triple-negative breast cancer (TNBC) cells, MDA-MB-231 using the new CUR-TMA cocrystal phase along with different CUR solid forms prepared in our previous works. The cytotoxicity and internalization assays conducted on 2D monolayers indicated that all CUR multicomponent solid forms except Curcumin-Folic Acid Dihydrate (CUR-FAD) (1:1) coamorphous solid exhibited enhanced bioavailability than unprocessed CUR. Cell invasion assay conducted on 3D tumor spheroid models showed that Curcumin-Hydroxyquinol (CUR-HXQ) cocrystal completely inhibited cell invasion whereas CUR-FAD (1:1) coamorphous solid induced enhanced invasion of cells from spheroid models.false2D monolayer | 3D tumor model | Cell invasion | Coamorphous solid | Cocrystal | Curcumin | Trimesic acidArticle1873347625 September 202028119667arJournal28